HLA-A*0201 & B2M & KRAS (KLVVVGAGGV) Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| IMVT-1402 | HL-161 ANS; IMVT-1402 | Phase 2 Clinical | Immunovant Sciences Gmbh, HanAll Biopharma Co Ltd | Autoimmune Diseases; Graves Disease | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Efgartigimod alfa | ARGX-113; EFG PH20; EFG PH20 SC; PH20 SC; ARGX-113-2308 | Approved | Argenx Se | VYVGART HYTRULO, VYVDURA, VYVGART, 卫伟迦 | United States | Myasthenia Gravis | Argenx BV | 2021-12-17 | Graves Ophthalmopathy; Tachycardia; Pemphigus; Thrombocytopenia; Guillain-Barre Syndrome; Eye Diseases; Nephrotic Syndrome; Muscular Diseases; Pemphigoid, Bullous; Optic Neuritis; Glomerulonephritis, Membranous; Rejection of organ transplantation; Purpura, Thrombocytopenic, Idiopathic; Lupus Nephritis; Scleroderma, Systemic; Stiff-Person Syndrome; Sjogren's Syndrome; Postural Orthostatic Tachycardia Syndrome; Polyneuropathies; Myositis; Nephrosis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Myasthenia Gravis | Details |
| Rozanolixizumab | UCB-7665 | Approved | Ucb Sa | RYSTIGGO | United States | Myasthenia Gravis | Ucb Inc | 2023-06-27 | Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic; Encephalitis; Fibromyalgia | Details |
| Efgartigimod alfa/Hyaluronidase | Approved | Argenx BV | VYVDURA, VYVGART HYTRULO | United States | Myasthenia Gravis | Argenx BV | 2023-06-20 | Myasthenia Gravis | Details |